Want to see ANRO full AI Analyst Report?

Alto Neuroscience, Inc. (ANRO) Price & Analysis

572 Followers

ANRO Stock Chart & Stats

$27.72

-$0.09(-1.99%)

At close: Jan 08 4:00 PM EST

$27.72

-$0.09(-1.99%)

Day’s Range― - ―

52-Week Range$2.20 - $28.44

Previous CloseN/A

Volume104.17K

Average Volume (3M)2.30M

Market Cap

$926.13M

Enterprise Value$506.63M

Total Cash (Recent Filing)$263.76M

Total Debt (Recent Filing)$5.69M

Price to Earnings (P/E)―

Beta2.08

Next Earnings

Aug 19, 2026

EPS Estimate

-0.72

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.48

Shares Outstanding35,093,940

10 Day Avg. Volume557,199

30 Day Avg. Volume2,303,174

Financial Highlights & Ratios

PEG Ratio0.66

Price to Book (P/B)3.40

Price to Sales (P/S)0.00

P/FCF Ratio-9.92

Enterprise Value/Market Cap0.55

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-1.78K

Enterprise Value/Ebitda-7.11

Forecast

1Y Price Target

$34.78

Price Target Upside25.46% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering11

EPS Forecast (FY)-2.98

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Biomarker-driven Precision PlatformAlto's biomarker-driven approach is a durable competitive advantage in neuropsychiatry: stratifying patients reduces heterogeneity in trials, improves signal detection, and increases the odds of clinical success. Over 2–6 months this supports partner interest and more efficient development paths.

Low Leverage, Strong CapitalizationA low-debt balance sheet materially reduces near-term insolvency risk and preserves optionality. With modest leverage and improved equity capitalization, Alto can fund near-term trials, pursue partnerships on better terms, and avoid urgent dilutive financings while advancing lead programs.

Board Expertise EnhancedAdding an experienced biotech leader to the board strengthens governance and strategic execution. Miller's drug-development and corporate strategy background can improve program prioritization, partner negotiations, and operational oversight—benefits that persist across clinical cycles.

Bears Say

Pre-revenue With Widening LossesAlto remains pre-revenue with losses that more than doubled TTM versus 2023, reflecting increasing R&D spend without offsetting income. This structural deficit increases likelihood of future financing, dilutive capital raises, and constrains long-term return prospects absent clinical success or partnership monetization.

Persistent Heavy Cash BurnSustained negative operating and free cash flow at scale creates ongoing runway pressure. Even with low debt, continued burn forces strategic tradeoffs: pausing programs, accelerating partner deals, or raising capital—each of which can dilute shareholders or slow development progress over the next several quarters.

Clinical Setback And Pipeline ConcentrationA Phase 2 miss for ALTO-101 and the decision to seek partners while reallocating to ALTO-207 concentrates clinical risk into the lead program. Dependence on a single Phase 2b entry increases binary outcome risk; failure or delay in ALTO-207 would materially impair value creation and strategic momentum.

Alto Neuroscience, Inc. News

Alto Neuroscience highlights publication in Nature Medicine on Prime-Praxol

Alto Neuroscience (ANRO) highlighted the publication in Nature Medicine of Prime-Praxol, an independent, randomized, double-blind, placebo-controlled trial of...

16d ago

ANRO

Alto Neuroscience Appoints Andrew Miller to Board

Alto Neuroscience, Inc. ( ($ANRO) ) just unveiled an announcement. On May 27, 2026, Alto Neuroscience, Inc. expanded...

1M ago

ANRO

Alto Neuroscience appoints Miller to Board of Directors

Alto Neuroscience (ANRO) announced the appointment of Andrew Miller, Ph.D. to its Board of Directors, effective May 27,...

1M ago

ANRO

Alto Neuroscience Buy Rating Reiterated as Analyst Highlights De-Risked Pipeline, Strong Cash Runway and Maintains $50 Price Target

H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on ANRO stock, giving a Buy rating on...

1M ago

ANRO

Alto Neuroscience price target lowered to $33 from $35 at BofA

BofA analyst Tazeen Ahmad lowered the firm’s price target on Alto Neuroscience (ANRO) to $33 from $35 and...

1M ago

ANRO

Alto Neuroscience price target lowered to $36 from $38 at Baird

Baird lowered the firm’s price target on Alto Neuroscience (ANRO) to $36 from $38 and keeps an Outperform...

1M ago

ANRO

Alto Neuroscience price target raised to $24 from $21 at Wedbush

Wedbush analyst Laura Chico raised the firm’s price target on Alto Neuroscience (ANRO) to $24 from $21 and...

2M ago

ANRO

Alto Neuroscience: Buy Rating Reiterated as Lead Asset Advances and Cash Runway Extends; $28 Price Target Maintained

In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Alto Neuroscience, Inc., with...

2M ago

ANRO

Ritu Baral Reiterates Buy on Alto Neuroscience, Citing Pivotal ALTO-207 Phase 2b Trial in TRD and Strong Cash Runway Through 2029

TD Cowen analyst Ritu Baral has maintained their bullish stance on ANRO stock, giving a Buy rating yesterday....

2M ago

ANRO

Alto Neuroscience Shareholders Shape Governance and Equity Plans

Alto Neuroscience, Inc. ( ($ANRO) ) has shared an announcement. On May 12, 2026, Alto Neuroscience, Inc. held...

2M ago

ANRO

Alto Neuroscience reports Q1 EPS (80c) vs (56c) last year

“2026 is off to a strong start across our pipeline, highlighted by the initiation of the Phase 2b...

2M ago

ANRO

Alto Neuroscience initiated with a Buy at BofA

BofA analyst Tazeen Ahmad initiated coverage of Alto Neuroscience (ANRO) with a Buy rating and $35 price target...

2M ago

ANRO

Alto Neuroscience presents Phase 2a data for ALTO-207 in MDD

Alto Neuroscience (ANRO) announced the presentation of data from a randomized, single-blind, placebo-controlled Phase 2a trial of ALTO-207...

2M ago

ANRO

Alto Neuroscience participates in a conference call with H. C. Wainwright

Healthcare Analyst Trucchio holds a conference call with CEO Etkin to discuss Alto’s precision psychiatry pipeline on May...

2M ago

ANRO

ANRO FAQ

What was Alto Neuroscience, Inc.’s price range in the past 12 months?

Alto Neuroscience, Inc. lowest stock price was $2.20 and its highest was $28.44 in the past 12 months.

What is Alto Neuroscience, Inc.’s market cap?

Alto Neuroscience, Inc.’s market cap is $926.13M.

When is Alto Neuroscience, Inc.’s upcoming earnings report date?

Alto Neuroscience, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 49 days.

How were Alto Neuroscience, Inc.’s earnings last quarter?

Alto Neuroscience, Inc. released its earnings results on May 13, 2026. The company reported -$0.8 earnings per share for the quarter, missing the consensus estimate of -$0.536 by -$0.264.

Is Alto Neuroscience, Inc. overvalued?

According to Wall Street analysts Alto Neuroscience, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Alto Neuroscience, Inc. pay dividends?

Alto Neuroscience, Inc. does not currently pay dividends.

What is Alto Neuroscience, Inc.’s EPS estimate?

Alto Neuroscience, Inc.’s EPS estimate is -0.72.

How many shares outstanding does Alto Neuroscience, Inc. have?

Alto Neuroscience, Inc. has 35,093,940 shares outstanding.

What happened to Alto Neuroscience, Inc.’s price movement after its last earnings report?

Alto Neuroscience, Inc. reported an EPS of -$0.8 in its last earnings report, missing expectations of -$0.536. Following the earnings report the stock price went down -7.227%.

Which hedge fund is a major shareholder of Alto Neuroscience, Inc.?

Currently, no hedge funds are holding shares in ANRO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Alto Neuroscience, Inc. Stock Smart Score

Outperform

Fundamentals

Return on Equity

-47.22%

Trailing 12-Months

Asset Growth

60.70%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Alto Neuroscience, Inc.

Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.

Alto Neuroscience, Inc. (ANRO) Earnings & Revenues

Historic Earnings Reports

ANRO Stock 12 Month Forecast

Average Price Target

$34.78

▲(25.46% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","26":"$26","51":"$51","13.5":"$13.5","38.5":"$38.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34.77777777777778,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$34.78</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$24.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,13.5,26,38.5,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.8,22.123076923076923,24.446153846153848,26.76923076923077,29.092307692307692,31.415384615384614,33.738461538461536,36.06153846153846,38.38461538461539,40.707692307692305,43.030769230769224,45.35384615384615,47.676923076923075,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.8,20.952136752136752,22.104273504273504,23.256410256410255,24.40854700854701,25.56068376068376,26.712820512820514,27.864957264957265,29.017094017094017,30.16923076923077,31.32136752136752,32.473504273504275,33.62564102564102,{"y":34.77777777777778,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.8,20.123076923076923,20.446153846153848,20.76923076923077,21.092307692307692,21.415384615384617,21.73846153846154,22.06153846153846,22.384615384615387,22.70769230769231,23.03076923076923,23.353846153846156,23.676923076923078,{"y":24,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.6,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.05,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.88,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.07,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.19,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.04,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.81,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.63,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.41,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.94,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.8,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >